Oncology Automation Market Witnesses Surge with Global Cancer Burden

Oncology Automation Market Size, Key Players with Insights and Growth

The global oncology automation market size is calculated at US$ 2.82 billion in 2024, grew to US$ 3.12 billion in 2025, and is projected to reach around US$ 7.77 billion by 2034. The market is expanding at a CAGR of 10.68% between 2025 and 2034.

The rising incidence of cancer globally and the growing demand for accuracy and effectiveness in cancer treatment methods are the key growth factors propelling this oncology automation market. Technological developments and the incorporation of AI and machine learning in healthcare are also driving the need for automation in oncology. An essential part of contemporary healthcare is the use of automated systems in oncology, which reduce human error and improve the course of treatment.

Key Takeaways

• Oncology automation market to crossed USD 2.82 billion by 2024.
• Market projected at USD 7.77 billion by 2034.
• CAGR of 10.68% expected in between 2025 to 2034.
• North America led the oncology automation market with a revenue of approximately 45%.
• Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
• By application, the chemotherapy segment led the market with a revenue of approximately 30% in 2024.
• By application, the immunotherapy segment is expected to grow at the fastest CAGR during the forecast period.
• By technology, the artificial intelligence (AI) segment led the market with a revenue of approximately 35% in 2024.
• By technology, the machine learning segment is expected to grow at the fastest CAGR during the forecast period.
• By end-user, the hospitals segment led the oncology automation market with a revenue of approximately 40% in 2024.
• By end-user, the homecare settings segment is expected to grow at the fastest CAGR during the forecast period.

Quick Facts Table

What is Meant by Oncology Automation?

The oncology automation market is driven by the increasing global cancer prevalence, demand for precision and efficiency in treatment procedures, advancements in AI, robotics, and machine learning, and the need for standardized and reproducible diagnostics. The market encompasses technologies and solutions designed to automate various processes within oncology care. This includes the automation of diagnostics, treatment planning, radiation therapy, chemotherapy preparation, and patient management. The aim is to enhance precision, reduce human error, improve efficiency, and streamline workflows in oncology departments and clinics.

Oncology Automation Market Outlook

• Industry Growth Overview: From 2025 to 2034, the market, which encompasses robotics, AI, and informatics, is anticipated to grow rapidly and with great specificity. The need for more effective cancer diagnosis and treatment, the growing incidence of cancer, and the trend towards personalised medicine are important motivators.
• Global Expansion: Due to its robust infrastructure and research and development, North America currently leads the global oncology automation market, which is expanding rapidly across all regions. Europe is right behind, with growth fueled by government programmes and an emphasis on sustainability. Rapid urbanisation, industrialisation, and rising technological investments, especially in China and India, are making the Asia-Pacific region a high-growth region.
• Major Investors: Major investors in the oncology automation market include pharmaceutical companies like Novartis and AstraZeneca, healthcare giants Siemens Healthineers and Medtronic, and well-known venture capital firms like OrbiMed and RA Capital Management. These investors fund surgical robots and diagnostic artificial intelligence (AI).

Major Trends in the Oncology Automation Market?

• Rising cancer cases: Automation is becoming highly essential due to rising cancer cases. As more and more cancer cases are going to be diagnosed, healthcare burden will increase. Automation will become highly essential for reducing work burden as well as financial burden on healthcare professionals and healthcare providers.
• The number of cancer cases worldwide is expected to increase by roughly 61% from 20 million in 2022 to 30.5 million by 2050, mostly due to ageing and population growth. The American Cancer Society estimates that by 2050, there will be 35 million new cases of cancer worldwide, up from about 20 million in 2022. According to data from the Global Burden of Disease (GBD) study, 30.5 million new cases of cancer are expected to be diagnosed by 2050, a 77% increase from 2022's projection of over 35 million cases.
• In August 2025, the National Cancer Grid (NCG) and IndiaAI's Independent Business Division (IBD) have launched the Cancer AI & Technology Challenge (CATCH) Grant Programme in a significant effort to incorporate state-of-the-art technology into oncology. The goal of the initiative is to expedite the creation and application of Artificial Intelligence (AI) solutions that will enhance cancer screening, diagnosis, treatment support, and operational efficiency throughout the nation's healthcare system.

Oncology Research Investments: Public & Private

Segmental Insights

Why was Chemotherapy Dominant in the Market in 2024?

By application, the chemotherapy segment was dominant in the oncology automation market with a revenue of approximately 30% in 2024. With its accuracy, usefulness, speed, and affordability, the SmartCompounders raises the bar for automated cytotoxic drug preparation. It provides technicians and pharmacists with the resources they need to expedite, improve the process, and get rid of mistakes in dose amounts and medicine identification.

By application, the immunotherapy segment is expected to grow at the fastest CAGR during the forecast period. By examining genomic, transcriptomic, and proteomic data, AI has made a substantial contribution to the discovery of biomarkers that forecast the effectiveness of immunotherapy. Additionally, it predicts the best treatment regimens, optimising combo medicines. Predictive models powered by AI aid in evaluating how well patients respond to immunotherapy, directing medical judgement and reducing adverse effects. AI also makes it easier to find new therapeutic targets, such neoantigens, which makes it possible to create customised immunotherapies.

Which Technology Segment Dominated the Market in 2024?

By technology, the artificial intelligence (AI) segment was dominant in the oncology automation market with a revenue of approximately 35% in 2024. Rapid advancements in AI integration in healthcare are changing several facets of medical oncology. From personalised therapy suggestions to diagnostic assistance, AI systems are quickly becoming indispensable resources for oncologists. These technologies advance the area of cancer care by increasing the accuracy of diagnoses, expediting the planning of therapies, and customising care for each patient.

By technology, the machine learning segment is expected to grow at the fastest CAGR in the oncology automation market during the forecast period. Machine learning, a subset of artificial intelligence (AI), is becoming more and more important in the diagnosis and management of different cancers. It is anticipated that machine learning would become a crucial tool for medical professionals. When compared to conventional staging techniques, the ML model has already improved patient prognostic prediction. The use of ML might potentially have a significant positive impact on the direct synthesis of the required medicinal compounds (small molecule mixtures) at the point of treatment.

What made the Hospitals Segment Dominant in the Market in 2024?

By end-user, the hospitals segment was dominant in the oncology automation market with a revenue of approximately 40% in 2024. Well-known cancer centres are automating patient care, diagnostic, surgical, and administrative processes. The use of AI for precision oncology at Apollo Cancer Centre, robotic surgery and diagnostics at SSO Cancer Hospital, and robotic devices like the DaVinci Surgical System for minimally invasive procedures at other medical facilities are a few examples.

By end-user, the homecare settings segment is expected to grow at the fastest CAGR during the forecast period. Home health agencies can increase their productivity and profitability by implementing automation and artificial intelligence. Even with limited resources, these technologies will enable them to make the most impact possible, optimise operations, and eventually improve their financial health, opening the door for expansion.

Regional Insights

Which Factors are Responsible for North America’s Dominance?

North America dominated the oncology automation market in 2024, with a revenue of approximately 45%. Favourable reimbursement policies, significant government support, and sophisticated digital infrastructure are the main drivers of the region's impressive performance. Along with strong federal and state-level initiatives supporting AI integration in oncology, the US market benefits from significant investment in healthcare technology and research. In a similar vein, Canada's market expansion is facilitated by its encouraging government policies and investments in healthcare innovation.

What are the U.S. Oncology Automation Market Trends?

The growing incidence of cancer, the need for efficiency, the use of advanced technologies like artificial intelligence, and the trend towards personalised medicine are all driving growth in the U.S. oncology automation market. The U.S. government has also made substantial investments in cancer research in 2024 and 2025, with the National Cancer Institute (NCI) receiving a $7.22 billion budget for both fiscal years.

Rising Government Initiative is Driving Canada

In April 2025, Canada's Immunotherapy Network, BioCanRx, is pleased to announce $12.5 million in new funding for four core facilities and 20 research projects. 13 new projects chosen from an open call for proposals held in late 2024 are among the funded projects, including seven that will expand on previously funded work. These innovative Canadian initiatives will boost the development of immunotherapy as a cancer treatment and increase Canada's ability to produce state-of-the-art biotherapeutic solutions.

Rising Government Initiatives are Driving the Asia Pacific

Asia Pacific is estimated to host the fastest-growing oncology automation market during the forecast period. with swift healthcare digitisation and growing investments in cancer care infrastructure. The region is experiencing an increase in the incidence of cancer, which is driving the need for oncology automation. In an attempt to improve patient outcomes, nations like China, India, and Japan are adopting oncology information systems. Growing government programmes and financing for healthcare modernisation also promote growth. Additionally, Asia is using more advanced oncology solutions due to increased partnerships with foreign technology vendors.

Oncology Automation Market Value Chain Analysis

R&D

From basic research to clinical deployment, research and development (R&D) is a multi-phase process that advances oncology automation. Artificial intelligence (AI)-based automation tools are being used in clinical trials, diagnosis, and treatment, among other areas of oncology.

Key Companies Include: Siemens Healthineers, Medtronic, Roche Diagnostics, Tempus, Bristol-Myers Squibb, Intuitive Surgical, Flatiron Health, Onc.AI, Orakl Oncology, AstraZeneca, etc.

Distribution to Hospitals, Clinics, ASCs

Distributing oncology automation systems, equipment, and software to clinics, hospitals, and ASCs is a difficult process that is influenced by various healthcare providers' particular requirements as well as stringent regulatory requirements. Distributors and manufacturers must follow different routes for software and physical hardware, with supply chain management, compliance, and customer integration being crucial at every stage.

Patient Support and Services

Through appointment scheduling, communication simplification, and administrative task automation, automation improves patient support in oncology while freeing up clinical staff and improving the patient experience. The steps listed below show how automation helps patients at every stage of their cancer journey, from early diagnosis to ongoing monitoring.

Top Vendors in the Oncology Automation Market & Their Offerings

• Varan Medical Systems: Offers informatics software and AI-powered radiotherapy systems like Ethos to automate and optimise clinical decision-making and cancer treatment processes.
• Elekta AB: Provides intelligently automated treatment delivery systems (Unity) and oncology software (Elekta ONE OIS) for effective, individualised radiation therapy.
• Acuray Incorporated: Inventor of robotic radiosurgery systems (CyberKnife) that use AI-powered real-time motion synchronisation to adjust for tumour and patient movement while undergoing treatment.
• Intuitive Surgical, Inc.: Creates the da Vinci robotic surgical system, which gives surgeons better vision, dexterity, and accuracy for minimally invasive oncology procedures.
• Medtronic plc: Develops robotic-assisted surgery platforms (Hugo) for minimally invasive procedures and AI-powered endoscopy systems (GI Genius) to aid in the early detection of cancer.

Top Companies in the Oncology Automation Market

• Varian Medical Systems
• Elekta AB
• Accuray Incorporated
• Intuitive Surgical, Inc.
• Medtronic plc
• Siemens Healthineers AG
• Brainlab AG
• ViewRay, Inc.
• C-RAD AB
• IBA Worldwide
• Mevion Medical Systems, Inc.
• RefleXion Medical, Inc.
• RaySearch Laboratories AB
• Mirada Medical Ltd.
• Vision RT Ltd.
• ZAP Surgical Systems, Inc.
• Theragenics Corporation
• CureMetrix, Inc.
• Xcision Medical Systems, LLC
• Tempus AI

Recent Developments in the Oncology Automation Market

• In July 2025, in an effort to revolutionise cancer diagnosis and treatment, One Biosciences has obtained €15 million in Series A funding to grow its AI-powered single-cell transcriptomic platform, OneMap.
• In April 2025, to improve cancer registry operations through automation and AI-powered data management, Elekta announced a partnership with Azra AI, the only end-to-end oncology workflow automation platform in the industry.

Segments Covered in the Report

By Application

• Chemotherapy
• Radiation Oncology
• Surgical Oncology
• Immunotherapy
• Targeted Therapy 

By Technology

• Artificial Intelligence (AI)
• Machine Learning (ML)
• Robotics
• Flow Cytometry
• Data Analytics

By End-User

• Hospitals
• Oncology Clinics
• Research Institutions
• Home Care Settings

By Region 

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait